We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App





Sebia Displays Automated, High Throughput Capillary Electrophoresis (CE) Instruments at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 12 Apr 2022
Print article
Image: Sebia at EUROMEDLAB 2022 (Photo courtesy of Sebia)
Image: Sebia at EUROMEDLAB 2022 (Photo courtesy of Sebia)

Sebia (Lisses, France) displayed its capillary electrophoresis (CE) instruments designed to provide complete automation, with fast protein separation at high resolution at EUROMEDLAB 2022.

CE allows a rapid and accurate signature-based measurement for major chronic diseases diagnosis and monitoring and is routinely used in clinical laboratories for screening of serum and other fluids for protein abnormalities. At EUROMEDLAB 2022, Sebia demonstrated CAPILLARYS 3 TERA MC configuration that allows the combination of one to three CAPILLARYS 3 TERA instruments to a Sebia loader, with a loading capacity of 528 samples in one row. This high volume workcell provides three hours autonomy on HbA1c, and hemoglobin testing, and more than two hours on proteins, processing up to 528 samples in one go. The system can be fed continuously with additional racks, and the reagent management system allows ad-hoc reagent addition at any time, without interruption.

Sebia also highlighted its CAPILLARYS 3 DBS high throughput solution for newborn hemoglobin disorders screening. CE is also a proven technology for hemoglobin disorders screening and provides high quality results. Sebia CAPILLARYS 3 DBS is the latest generation of instrument dedicated to newborn hemoglobin screening, offering a smooth workflow and excellent analytical features. The CAPILLARYS 3 DBS instrument is an automated, multitasking capillary electrophoresis instrument using 12 capillaries for multiple simultaneous hands-free electrophoretic separations at high throughput.

The CAPILLARYS 3 DBS enables the analysis of samples from microplate wells and provides fully automated electrophoresis separation, from the dried blood spots on filter paper (Guthrie card) through to the final electrophoretic pattern: sample identification, sample dilution, sample incubation, capillary washing, sample injection into the capillaries, migration, detection, processing of the results, and transfer over the computer interface. This instrument is an interesting alternative to commonly used technology such as IEF and HPLC for all the laboratories involved in newborn hemoglobin screening, bringing seamless sample traceability, high quality results, and high throughput while offering a reduced hands-on time.

Related Links:
Sebia 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.